Therefore, the analysis of circulating EPCs might offer a new therapeutic target in PAD, while NPT synergistically with CRP and other conventional PAD biomarkers might provide useful information on the atherosclerosis initiation and progression. The gene discussed is CRP; the disease is peripheral arterial disease.